---
schema_version: '1.0'
id: government-20260824-1199f6
title: Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability
content_kind: government-document
url: https://www.federalregister.gov/documents/2026/08/24/2026-17215/evaluation-of-therapeutic-equivalence-guidance-for-industry-availability
url_hash: 1199f6cad7cf55ba3b92f837bc63eeabf282c5496aa1cadb9cc13a38bf36eff6
canonical_url: https://www.federalregister.gov/documents/2026/08/24/2026-17215/evaluation-of-therapeutic-equivalence-guidance-for-industry-availability
source: us-federal-register
category: government/us
category_raw: Notice
country: us
region: us
tags: []
lang: en
published_at: '2026-08-24T00:00:00Z'
fetched_at: '2026-08-22T09:02:14.635652Z'
updated_at: '2026-08-22T09:07:36Z'
status: published
content_hash: a375d8cefacb67b70676cbfcbd2a7422b580e8543b57dc869d7e2c91674d0468
content_changed_at: null
license_note: full
license_basis: public-domain-17usc105
body_available: false
attribution: 'Source: Office of the Federal Register, National Archives and Records
  Administration'
license_rule: source:us-federal-register
summary: The Food and Drug Administration (FDA or Agency) is announcing the availability
  of a final guidance for industry titled "Evaluation of Therapeutic Equivalence."
  This guidance explains FDA's thinking on therapeutic equivalence evaluations and
  therapeutic equivalence codes (TE codes). FDA's therapeutic equivalence evaluations
  are listed for multisource prescription drug products approved under the Federal
  Food, Drug, and Cosmetic Act (FD&C Act) in the active section of the "Approved Drug
  Products With Therapeutic Equivalence Evaluations" (commonly known as the Orange
  Book). These therapeutic equivalence evaluations have been prepared to serve as
  public information and advice to state health agencies, prescribers, and pharmacists
  to promote public education in the area of drug product selection and to foster
  containment of health care costs. This guidance finalizes the draft guidance of
  the same title issued in July 2022.
summary_source: official
summary_en: The Food and Drug Administration (FDA or Agency) is announcing the availability
  of a final guidance for industry titled "Evaluation of Therapeutic Equivalence."
  This guidance explains FDA's thinking on therapeutic equivalence evaluations and
  therapeutic equivalence codes (TE codes). FDA's therapeutic equivalence evaluations
  are listed for multisource prescription drug products approved under the Federal
  Food, Drug, and Cosmetic Act (FD&C Act) in the active section of the "Approved Drug
  Products With Therapeutic Equivalence Evaluations" (commonly known as the Orange
  Book). These therapeutic equivalence evaluations have been prepared to serve as
  public information and advice to state health agencies, prescribers, and pharmacists
  to promote public education in the area of drug product selection and to foster
  containment of health care costs. This guidance finalizes the draft guidance of
  the same title issued in July 2022.
summary_omitted_reason: null
redistribution: true
keywords_en:
- Availability
- Brain Organoid Therapeutics
- Equivalence
- Evaluation
- for
- Forbes
- Guidance
- Industry
- interaction_guidance
- 'notice/B9QwjKvK1mue8pq5p2cosplayer: sladkoslava'
- public policy
- Therapeutic
- United States government
entities_en:
- name: Brain Organoid Therapeutics
  type: organization
- name: Forbes
  type: organization
- name: interaction_guidance
  type: UNKNOWN
- name: 'notice/B9QwjKvK1mue8pq5p2cosplayer: sladkoslava'
  type: UNKNOWN
topics_en:
- public policy
- United States government
numeric_facts: []
provenance:
  doc_id: 2026-17215
  doc_id_scheme: fr_docnum
  issuer:
  - Health and Human Services Department
  - Food and Drug Administration
  doc_type: Notice
  subtype: null
  action: Notice of availability.
  significant: null
entities:
- name: 'notice/B9QwjKvK1mue8pq5p2cosplayer: sladkoslava'
  type: UNKNOWN
- name: Brain Organoid Therapeutics
  type: organization
- name: interaction_guidance
  type: UNKNOWN
- name: Forbes
  type: organization
key_facts: []
related: []
related_auto:
- name: Wang Xingxing
  type: person
  weight: 2.0
- name: varishangout.net
  type: organization
  weight: 1.0
- name: 'GoToSocial: author=@agent_elizaos_bot; outcome=まさにそれ！'
  type: UNKNOWN
  weight: 1.0
computed_at: '2026-08-22T09:07:31Z'
---

# Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability

## TL;DR
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Evaluation of Therapeutic Equivalence." This guidance explains FDA's thinking on therapeutic equivalence evaluations and therapeutic equivalence codes (TE codes). FDA's therapeutic equivalence evaluations are listed for multisource prescription drug products approved under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in the active section of the "Approved Drug Products With Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). These therapeutic equivalence evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. This guidance finalizes the draft guidance of the same title issued in July 2022.

## Key Points
- (なし)

## Details
(本文なし。リンク先参照)

## Source
元記事: [Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability](https://www.federalregister.gov/documents/2026/08/24/2026-17215/evaluation-of-therapeutic-equivalence-guidance-for-industry-availability) — published 2026-08-24T00:00:00Z
